Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps his Department has taken under the Health Service Medical Supplies (Costs) Act 2017 to collect information on the Concordia/Amdipharm Mercury Group and liothyronine.

The information powers in the Health Service Medical Supplies (Costs) Act 2017 can only be implemented by regulations. At the end of last year the Department consulted on those regulations and we are currently analysing the responses to that consultation.

The Competition and Markets Authority has provisionally found that that Concordia abused its dominant position to overcharge the National Health Service by millions for liothyronine tablets. A provisional decision does not necessarily lead to an infringement decision. Where companies have breached competition law, the Department will seek damages and invest that money back into the NHS.